Insights From the Pharmaceutical Space: New Research on Alcobra, Alder, Aldeyra, Alexion, Alexza

NEW YORK, February 3, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Alcobra (NASDAQ: ADHD), Alder (NASDAQ: ALDR), Aldeyra (NASDAQ: ALDX), Alexion (NASDAQ: ALXN), and Alexza (NASDAQ: ALXA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ADHD Research Report: ( http://get.analystsreview.com/pdf/?c=Alcobra&d=03-Feb-2015&s=ADHD ),

ALDR Research Report: ( http://get.analystsreview.com/pdf/?c=Alder&d=03-Feb-2015&s=ALDR ),

ALDX Research Report: ( http://get.analystsreview.com/pdf/?c=Aldeyra&d=03-Feb-2015&s=ALDX ),

ALXN Research Report: ( http://get.analystsreview.com/pdf/?c=Alexion&d=03-Feb-2015&s=ALXN ),

ALXA Research Report: ( http://get.analystsreview.com/pdf/?c=Alexza&d=03-Feb-2015&s=ALXA ).

============

--

Analyst Update: Public Offerings, Private Placements, and Clinical Trials Data

Reviewed by: Rohit Tuli, CFA®  

The U.S. stocks ended higher on Monday helped by a late-session rally in the energy shares which also offset a fresh set of disappointing economic data. The Dow Jones Industrial Average rose 1.14% to close at 17,361.04, the S&P 500 increased 1.30% to close at 2,020.85, and the Nasdaq Composite gained 0.89% to end at 4,676.69. Energy shares led the advance, with the S&P 500 energy sector ending up nearly 3% following rise in the crude oil prices. Disappointing data on consumer spending and the manufacturing sector released on Monday weighed on the market early in the session. The European stocks ended on a mixed note on Monday amid continued uncertainty over Greece's debt negotiations and rising worries over the health of global economies. The pan-European Euro Stoxx 600 Index closed largely flat. In Asia, markets were mostly under pressure after fresh data raised concerns over China's manufacturing sector.

Israel-based biopharmaceutical Company Alcobra Ltd (Alcobra) reported that it has closed its previously announced public offering of ordinary shares. The Company said it sold 7.5 million ordinary shares in the offering, including 975,000 shares that were issued upon the full exercise by the underwriters of their over-allotment option.

Alder BioPharmaceuticals Inc (Alder), a clinical-stage biopharmaceutical company, announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 0.90 million shares of common stock.

Aldeyra Therapeutics, Inc. (Aldeyra) announced the closing of its previously announced $2.0 million private placement of common stock and a warrant to purchase common stock. Aldeyra plans to use the proceeds for its upcoming Phase II clinical trials in Sjögren-Larsson Syndrome (SLS) and noninfectious anterior uveitis, working capital, and general corporate purposes.

Alexion Pharmaceuticals, Inc. (Alexion) announced that researchers will present new functional and quality-of-life data from clinical studies in children with hypophosphatasia (HPP) who were treated with asfotase alfa for at least three years at the Endocrine Society's 97th Annual Meeting and Expo (ENDO), to be held on March 5-8, 2015, in San Diego, California.

Alexza Pharmaceuticals, Inc. (Alexza) announced that it has initiated a Phase IIa study of AZ-002 (Staccato alprazolam), which is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS). ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED